Aptose Biosciences (NASDAQ:APTO) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research note published on Wednesday. The firm issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright restated a “buy” rating and issued a $2.00 price objective on shares of Aptose Biosciences in a report on Tuesday, December 10th.

Aptose Biosciences Price Performance

Shares of APTO opened at $0.22 on Wednesday. Aptose Biosciences has a one year low of $0.13 and a one year high of $2.48. The company has a 50-day simple moving average of $0.25 and a two-hundred day simple moving average of $0.41. The firm has a market capitalization of $13.24 million, a PE ratio of -0.07 and a beta of 0.87.

Hedge Funds Weigh In On Aptose Biosciences

A hedge fund recently bought a new stake in Aptose Biosciences stock. Armistice Capital LLC purchased a new stake in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 1,713,000 shares of the biotechnology company’s stock, valued at approximately $1,300,000. Armistice Capital LLC owned approximately 9.46% of Aptose Biosciences as of its most recent SEC filing. 26.62% of the stock is currently owned by institutional investors.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.